Advertisement

Vertex Pharmaceuticals Incorporated VRTX

Set alert

Price alert · VRTX

All alert types
558.88 USD +18.88 +3.50%

At close · Oct 30

554.00 -4.88 -0.87%

After hours · Oct 30, 5:48 PM ET

Bid
558.96 × 1
Ask
559.11 × 1
549.89 Day range 563.80
409.47 52-week range 558.88
YTD
+23.28%
1 year
+33.10%
Open
550.73
Prev close
540.00
Mkt cap
141.56B
Vol
3.03M
Avg vol
1.16M
EPS
17.17
P/E
32.55
Div yield
0.00%
More statistics
Low
549.89
High
563.80
Forward P/E
27.40
Beta
0.28
Short ratio
3.66
Inst. own
98.16%
Dividend
0.00
Ex-div date
Earnings
Nov 2, 2026
50-d avg
522.84
200-d avg
478.67
1y target
571.46

5Y chart

Chart tools
Interval

Events in this range
  • Aug 4, 2025Earnings: 4.52; estimate 4.29; surprise 5.36%
  • Nov 3, 2025Earnings: 4.8; estimate 4.57; surprise 5.03%
  • Feb 12, 2026Earnings: 5.03; estimate 5.11; surprise -1.57%
  • May 4, 2026Earnings: 4.47; estimate 4.24; surprise 5.42%
  • Aug 3, 2026Earnings: 4.73; estimate 4.74; surprise -0.21%
  • Aug 4, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
  • Aug 4, 2026Rating: TD Cowen · Buy → Buy
  • Aug 5, 2026Rating: Barclays · Overweight → Overweight
  • Aug 5, 2026Rating: Truist Securities · Buy → Buy
  • Sep 28, 2026Rating: UBS · Buy → Buy
  • Oct 8, 2026Rating: RBC Capital · Outperform → Outperform
  • Nov 2, 2026Earnings: —; estimate 4.82; surprise —%
Signals (106)
NameDateAgo
MACD: Buy SignalOct 30, 20261 day ago
SMA: BullishOct 19, 20261 week ago
MACD: Sell SignalOct 5, 20263 weeks ago
SMA: BearishSep 28, 20261 month ago
SMA: BullishSep 21, 20261 month ago
SMA: BearishSep 14, 20261 month ago
RSI: OverboughtJun 29, 20264 months ago
SMA: BullishJun 22, 20264 months ago
MACD: Buy SignalJun 15, 20264 months ago
SMA: BullishMay 25, 20265 months ago
SMA: BearishMar 23, 20267 months ago
MACD: Sell SignalMar 16, 20267 months ago
SMA: BearishMar 2, 20268 months ago
SMA: BullishJan 19, 20269 months ago
SMA: BearishJan 12, 20269 months ago
SMA: BullishNov 24, 202511 months ago
SMA: BearishNov 17, 202511 months ago
SMA: BullishNov 10, 202511 months ago
MACD: Buy SignalOct 13, 20251 year ago
SMA: BullishSep 29, 20251 year ago
SMA: BearishAug 4, 20251 year ago
MACD: Sell SignalAug 4, 20251 year ago
SMA: BearishJul 28, 20251 year ago
MACD: Buy SignalJul 21, 20251 year ago
SMA: BullishJun 30, 20251 year ago
SMA: BullishJun 30, 20251 year ago
SMA: BearishMay 5, 20251 year ago
SMA: BearishMay 5, 20251 year ago
MACD: Sell SignalMay 5, 20251 year ago
SMA: BullishApr 7, 20251 year ago
SMA: BearishMar 31, 20251 year ago
SMA: BullishFeb 17, 20251 year ago
SMA: BearishFeb 10, 20251 year ago
SMA: BullishFeb 3, 20251 year ago
MACD: Buy SignalFeb 3, 20251 year ago
SMA: BullishJan 20, 20251 year ago
SMA: BearishNov 11, 20241 year ago
SMA: BearishNov 11, 20241 year ago
SMA: BullishNov 4, 20241 year ago
SMA: BearishOct 28, 20242 years ago
SMA: BullishOct 7, 20242 years ago
SMA: BearishSep 16, 20242 years ago
SMA: BullishSep 9, 20242 years ago
SMA: BearishSep 2, 20242 years ago
SMA: BullishAug 19, 20242 years ago
MACD: Sell SignalAug 12, 20242 years ago
SMA: BearishAug 5, 20242 years ago
RSI: OverboughtJul 8, 20242 years ago
RSI: OverboughtJun 3, 20242 years ago
MACD: Buy SignalMay 20, 20242 years ago
SMA: BullishMay 6, 20242 years ago
SMA: BullishApr 22, 20242 years ago
SMA: BearishApr 15, 20242 years ago
SMA: BearishMar 4, 20242 years ago
MACD: Sell SignalMar 4, 20242 years ago
RSI: OverboughtJan 8, 20242 years ago
SMA: BullishDec 11, 20232 years ago
SMA: BullishDec 11, 20232 years ago
MACD: Buy SignalDec 11, 20232 years ago
SMA: BearishDec 4, 20232 years ago
SMA: BearishNov 13, 20232 years ago
MACD: Sell SignalNov 13, 20232 years ago
MACD: Buy SignalOct 30, 20233 years ago
MACD: Sell SignalOct 23, 20233 years ago
MACD: Buy SignalOct 9, 20233 years ago
SMA: BullishOct 2, 20233 years ago
SMA: BearishSep 25, 20233 years ago
SMA: BullishSep 18, 20233 years ago
SMA: BearishSep 4, 20233 years ago
SMA: BullishAug 21, 20233 years ago
SMA: BearishAug 14, 20233 years ago
SMA: BullishAug 7, 20233 years ago
SMA: BearishJul 31, 20233 years ago
MACD: Sell SignalJul 31, 20233 years ago
SMA: BullishJul 10, 20233 years ago
SMA: BearishJul 3, 20233 years ago
SMA: BullishJun 12, 20233 years ago
SMA: BearishMay 22, 20233 years ago
MACD: Buy SignalApr 3, 20233 years ago
SMA: BullishMar 20, 20233 years ago
SMA: BullishMar 20, 20233 years ago
SMA: BearishFeb 6, 20233 years ago
SMA: BearishJan 30, 20233 years ago
SMA: BullishJan 16, 20233 years ago
SMA: BullishJan 9, 20233 years ago
SMA: BearishDec 19, 20223 years ago
SMA: BearishDec 12, 20223 years ago
MACD: Sell SignalDec 12, 20223 years ago
MACD: Buy SignalNov 14, 20223 years ago
MACD: Sell SignalNov 7, 20223 years ago
MACD: Buy SignalOct 31, 20224 years ago
SMA: BullishSep 26, 20224 years ago
SMA: BearishSep 19, 20224 years ago
SMA: BullishSep 5, 20224 years ago
SMA: BearishAug 22, 20224 years ago
MACD: Sell SignalJul 18, 20224 years ago
MACD: Buy SignalJul 4, 20224 years ago
SMA: BullishJun 20, 20224 years ago
SMA: BearishJun 6, 20224 years ago
SMA: BullishMay 23, 20224 years ago
SMA: BearishMay 2, 20224 years ago
RSI: OverboughtApr 25, 20224 years ago
RSI: OverboughtMar 14, 20224 years ago
SMA: BullishFeb 28, 20224 years ago
RSI: OverboughtFeb 28, 20224 years ago
SMA: BearishFeb 21, 20224 years ago

Key statistics

Market cap
141.56B
Enterprise value
130.99B
Trailing P/E
32.55
Forward P/E
27.40
PEG ratio
2.11
Price / sales
11.25
Price / book
6.99
EPS (TTM)
17.17
Beta
0.28
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
35.00%
Revenue (TTM)
12.59B
Revenue growth
12.50%
Free cash flow
2.63B
Total cash
7.85B
Total debt
1.98B
Return on equity
23.54%
Shares outstanding
253.30M
Short % of float
1.90%
50-day average
522.84
200-day average
478.67

Analyst view

Consensus: buy

Buy
Price target (mean) 571.46 +2.3% upside
Target (low)
350.00
Target (mean)
571.46
Target (high)
667.00
Ratings (0m) 32 26 buy · 4 hold · 2 sell
  • Strong buy6
  • Buy20
  • Hold4
  • Sell1
  • Strong sell1

Next earnings

Nov 2, 2026

Expected Nov 2, 2026. Consensus EPS estimate 4.75.

Earnings history

Financials — quick view

All financials
VRTX Revenue — quarterly 3.33B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
VRTX Net income — quarterly 1.10B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
VRTX EPS — quarterly 4.34
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

VRTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 2, 2026Sep 30, 20264.82———
Aug 3, 2026Jun 30, 20264.744.73-0.01-0.21%
May 4, 2026Mar 31, 20264.244.47+0.23+5.42%
Feb 12, 2026Dec 31, 20255.115.03-0.08-1.57%
Nov 3, 2025Sep 30, 20254.574.80+0.23+5.03%
Aug 4, 2025Jun 30, 20254.294.52+0.23+5.36%

Upgrades / downgrades

VRTX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 8, 2026RBC CapitalmainOutperformOutperform
Sep 28, 2026UBSmainBuyBuy
Aug 5, 2026Truist SecuritiesmainBuyBuy
Aug 5, 2026BarclaysmainOverweightOverweight
Aug 4, 2026TD CowenmainBuyBuy
Aug 4, 2026Cantor FitzgeraldmainOverweightOverweight

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
vrtx.com

News

Your note

Sign in to keep a note on VRTX — it syncs with the Stock Master app.

Insider holders

VRTX insider holders
InsiderRelationLatest transactionDateShares held
ALTSHULER DAVIDOfficerStock Award(Grant)Jan 21, 202634,477
ARBUCKLE STUART AChief Operating OfficerStock Award(Grant)May 12, 2025100,751
ATKINSON EDWARD MORROW IIIChief Technology OfficerSaleFeb 24, 202618,432
KEWALRAMANI RESHMAChief Executive OfficerSaleFeb 26, 202698,278
LEIDEN JEFFREY MOfficer and DirectorStock Award(Grant)Feb 16, 202638,784
LIU JOYOfficerSaleJun 30, 202619,131

Institution ownership

VRTX institution ownership
Holder% heldSharesValueReported
Capital World Investors10.29%26,115,01414.60BJun 29, 2026
Blackrock Inc.9.50%24,109,37313.47BJun 29, 2026
Capital Research Global Investors7.68%19,490,63710.89BJun 29, 2026
Vanguard Capital Management LLC6.53%16,580,7139.27BJun 29, 2026
State Street Corporation4.68%11,871,4596.63BJun 29, 2026
Invesco Ltd.3.17%8,043,0524.50BJun 29, 2026

Fund ownership

VRTX fund ownership
Holder% heldSharesValueReported
Growth Fund of America5.09%12,908,2377.21BSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%8,058,1284.50BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%6,576,5103.68BJun 29, 2026
AMERICAN BALANCED FUND2.14%5,428,8653.03BSep 29, 2026
Invesco QQQ Trust, Series 12.09%5,294,1262.96BSep 29, 2026
Amcap Fund1.87%4,734,9212.65BSep 29, 2026
Advertisement